A major Phase III clinical trial of a tau inhibitor aggregation therapy by Singapore's TauRx failed to meet its primary endpoint, though the work showed…

Singapore-based TauRx will update on Phase III studies of its tau aggregation inhibitor LMTX in a podium presentation at the Alzheimer’s Association…

Exceptions on 15 ingredients from a banned plant run by China's Zhejiang Hisun Pharmaceuticals have raised questions on the ability of inspectors to…

Reports that a sales representative at Abbott Laboratories in India cited work performance demands in a suicide note have reverberated among colleagues.

China Resources has teamed up with Australian investment bank Macquarie to buy a majority of cancer and cardio medical care provider GenesisCare in a $1.3…

China’s Jilin Zixin Pharmaceutical Industrial has splashed out $42 million to buy a Rhode Island-based high-definition genome mapping company, Nabsys 2.0.

Roche's top pharmaceutical executive said a likely timeline for a Herceptin biosimilar is late 2017.

Biocon said in its first-quarter earnings that biosimilar applications for Humira and Herceptin are due to be filed in the U.S. and EU in the company's…

Abbott Laboratories CEO Miles White noted weaker pediatric nutrition sales--milk powder--in China in the second quarter.